Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Baxter Acquisition Of NAVA Hinges On Approval of NeisVac-C in U.K.

  • News

Executive Summary

Baxter's acquisition of North American Vaccine is contingent upon the U.K. approval of NAVA's group C meningococcal conjugate vaccine NeisVac-C.

You may also be interested in...



Baxter Adds Vaccine Production Capacity Via Peptide Therapeutics Deal

Baxter is enhancing its vaccine production capacity via a $40 mil. equity investment in Peptide Therapeutics.

Baxter Adds Vaccine Production Capacity Via Peptide Therapeutics Deal

Baxter is enhancing its vaccine production capacity via a $40 mil. equity investment in Peptide Therapeutics.

Aventis Pasteur MSD Adds Chiron's Meng C and Flu Vaccines To Portfolio

Aventis Pasteur MSD will sell Chiron's meningococcal C vaccine Menjugate and adjuvanted influenza vaccine Fluad under a co-marketing agreement.

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS035188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By